Prelude Capital Management reveals significant shifts in Q3 and Q4 2022 holdings

In recent times, investment management and venture capital firms are becoming more open through mandated SEC filings that require disclosure of their investments, enabling investors to track their portfolio to a granular level. The 13F filings done on a quarterly basis indicate the portfolio holdings of investment managers worth over $100 million. In this blog post, we will take a closer look at the Q3 and Q4 2022 13F holdings of Prelude Capital Management, LLC.

Prelude Capital Management, LLC is a privately owned investment manager responsible for managing over $2.16 billion in assets. The firm caters to pooled investment vehicles, primarily focused on life science companies, prioritizing therapeutic platforms, and keeping an eye on other sectors such as biotech, medical devices, and related technology opportunities.

From the 13F filings, we discovered Prelude Capital Management's holdings in various public companies, explicitly analyzing their changes in Q3 vs. Q4 2022 for some of them. Our analysis shows significant changes in the fund's investments from one quarter to the other. Among notable changes, we observed a massive increase of 481.7% in the number of shares of the SPDR S&P 500 ETF TR. The QS ratio on the ETF also changed significantly from being bearish to bullish.

Another significant increase was in the number of shares of the VANGUARD INDEX FDS, which increased by 1,372 shares (0.51%) from Q3 to Q4 2022. The value of the shares in dollars increased from $87,073 to $93,666, a change of 7.6%. From our research, these two examples are the only holdings enjoyed by Prelude Capital Management, LLC that also appeared in the iShares trust that experienced a bullish trend.

Prelude Capital Management, LLC invested in other sectors such as the gaming industry, healthcare, and software. As earlier stated, the firm has a significant focus on companies in these sectors with a novel approach to therapies, medical and biotech researches, and related technologies. For the gaming industry, Prelude Capital Management invested in GAMESTOP CORP NEW through put contracts, owning a significant stake at the end of Q4 2022. In the healthcare sector, the fund acquired positions in ENERSYS, HCA HEALTHCARE INC, and 1LIFE HEALTHCARE INC through standard buying of shares. Prelude Capital Management's activities in the software industry included investing in EVO PMTS INC and EPAM SYS INC by acquiring their shares.

Conclusion

From our analysis, it is evident that Prelude Capital Management, LLC invested heavily in ETFs, pharmaceutical companies, and software, which isn't surprising, given the firm's life science focus. The fund's activities in Q4 2022 indicate high activity, with new positions and several changes to existing holdings. By remaining up-to-date with the SEC filings of other investment firms, investors can improve awareness of the market and plan accordingly.